Publication: Pharmacokinetic interactions between primaquine and chloroquine
Issued Date
2014-01-01
Resource Type
ISSN
10986596
00664804
00664804
Other identifier(s)
2-s2.0-84901280985
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Antimicrobial Agents and Chemotherapy. Vol.58, No.6 (2014), 3354-3359
Suggested Citation
Sasithon Pukrittayakamee, Joel Tarning, Podjanee Jittamala, Prakaykaew Charunwatthana, Saranath Lawpoolsri, Sue J. Lee, Warunee Hanpithakpong, Borimas Hanboonkunupakarn, Nicholas P.J. Day, Elizabeth A. Ashley, Nicholas J. White Pharmacokinetic interactions between primaquine and chloroquine. Antimicrobial Agents and Chemotherapy. Vol.58, No.6 (2014), 3354-3359. doi:10.1128/AAC.02794-13 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/34735
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pharmacokinetic interactions between primaquine and chloroquine
Other Contributor(s)
Abstract
Chloroquine combined with primaquine has been the standard radical curative regimen for Plasmodium vivax and Plasmodium ovale malaria for over half a century. In an open-label crossover pharmacokinetic study, 16 healthy volunteers (4 males and 12 females) aged 20 to 47 years were randomized into two groups of three sequential hospital admissions to receive a single oral dose of 30 mg (base) primaquine, 600 mg (base) chloroquine, and the two drugs together. The coadministration of the two drugs did not affect chloroquine or desethylchloroquine pharmacokinetics but increased plasma primaquine concentrations significantly (P≤0.005); the geometric mean (90% confidence interval [CI]) increases were 63% (47 to 81%) in maximum concentration and 24% (13 to 35%) in total exposure. There were also corresponding increases in plasma carboxyprimaquine concentrations (P≤0.020). There were no significant electrocardiographic changes following primaquine administration, but there was slight corrected QT (QTc) (Fridericia) interval lengthening following chloroquine administration (median [range]=6.32 [-1.45 to 12.3] ms; P<0.001), which was not affected by the addition of primaquine (5.58 [1.74 to 11.4] ms; P=0.642). This pharmacokinetic interaction may explain previous observations of synergy in preventing P. vivax relapse. This trial was registered at ClinicalTrials.gov under reference number NCT01218932. © 2014 Pukrittayakamee et al.